{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T22:49:10Z","timestamp":1791931750419,"version":"4.3.4"},"reference-count":10,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Med"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.medj.2026.101097","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T15:47:09Z","timestamp":1775836029000},"page":"101097","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Phase 3 study results for oral PCSK9 inhibition with enlicitide"],"prefix":"10.1016","volume":"7","author":[{"given":"Irina","family":"M\u00fcller-Kozarez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Laufs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.medj.2026.101097_bib1","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1056\/NEJMoa2511002","article-title":"A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide","volume":"394","author":"Navar","year":"2026","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.medj.2026.101097_bib2","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1001\/jama.2025.20620","article-title":"Efficacy and Safety of Oral PCSK9 Inhibitor Enlicitide in Adults With Heterozygous Familial Hypercholesterolemia: A Randomized Clinical Trial","volume":"335","author":"Ballantyne","year":"2026","journal-title":"JAMA"},{"key":"10.1016\/j.medj.2026.101097_bib3","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1007\/s00392-025-02686-5","article-title":"Treatment pathways of lipid-lowering therapies in Germany 2016-2022","volume":"115","author":"Katzmann","year":"2026","journal-title":"Clin. Res. Cardiol."},{"key":"10.1016\/j.medj.2026.101097_bib4","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1097\/CRD.0000000000000655","article-title":"New Oral PCSK9 Inhibitor: \u201cMK-0616\u201d","volume":"33","author":"Siddiqui","year":"2025","journal-title":"Cardiol. Rev."},{"key":"10.1016\/j.medj.2026.101097_bib5","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1161\/CIRCULATIONAHA.122.063372","article-title":"Orally Bioavailable Macrocyclic Peptide That Inhibits Binding of PCSK9 to the Low Density Lipoprotein Receptor","volume":"148","author":"Johns","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.medj.2026.101097_bib6","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.atherosclerosis.2023.01.001","article-title":"Efficacy, safety, adherence and persistence of PCSK9 inhibitors in clinical practice: A single country, multicenter, observational study (AT-TARGET-IT)","volume":"366","author":"Gargiulo","year":"2023","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.medj.2026.101097_bib7","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1016\/j.jacc.2025.03.499","article-title":"An Oral PCSK9 Inhibitor for Treatment of Hypercholesterolemia: The PURSUIT Randomized Trial","volume":"85","author":"Koren","year":"2025","journal-title":"JACC (J. Am. Coll. Cardiol.)"},{"key":"10.1016\/j.medj.2026.101097_bib8","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.jacc.2018.06.046","article-title":"Impact of Lipids on Cardiovascular Health: JACC Health Promotion Series","volume":"72","author":"Ference","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.medj.2026.101097_bib9","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.912785","article-title":"Trends in Ezetimibe Prescriptions as Monotherapy or Fixed-Dose Combination in Germany 2012-2021","volume":"9","author":"Katzmann","year":"2022","journal-title":"Front. Cardiovasc. Med."},{"key":"10.1016\/j.medj.2026.101097_bib10","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s00392-022-01993-5","article-title":"Use of fixed-dose combination antihypertensives in Germany between 2016 and 2020: an example of guideline inertia","volume":"112","author":"Mahfoud","year":"2023","journal-title":"Clin. Res. Cardiol."}],"container-title":["Med"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634026001005?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634026001005?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T08:59:52Z","timestamp":1778921992000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666634026001005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":10,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S2666634026001005"],"URL":"https:\/\/doi.org\/10.1016\/j.medj.2026.101097","relation":{},"ISSN":["2666-6340"],"issn-type":[{"value":"2666-6340","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase 3 study results for oral PCSK9 inhibition with enlicitide","name":"articletitle","label":"Article Title"},{"value":"Med","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medj.2026.101097","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101097"}}